Oral squamous cell carcinoma (OSCC) is the commonest subtype of oral cancer, mainly affecting older patients. It used to be a rare disease among individuals younger than 40 years, but recently increased incidences in this age group are being reported worldwide. The pathogenesis of OSCC affecting young patients remains controversial, and the well-known etiological factors for oral cancer, tobacco, and alcohol use are believed to play a minor role in the carcinogenesis of the neoplasm, suggesting that the etiology and the molecular basis of OSCC may differ between younger and older patients. Although several molecular markers and chromosomal abnormalities have been demonstrated to differ between both groups, most of the studies have failed to find significant differences. Moreover, divergent results have also been obtained regarding the presence of high-risk human papillomavirus infection in OSCC of young patients. Given these contradictory results and the limited methodological approaches of the majority of the studies, the exact difference between both age groups remains to be fully established. In this review, we evaluate the available data to establish the current evidence that might support the hypothesis that the molecular basis of OSCC in young patients (especially those under 40 years) differ from the older patients.
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| INTRODUCTION
Oral squamous cell carcinoma (OSCC) is the commonest malignant neoplasm of the oral cavity and the eighth most prevalent cancer worldwide.
1,2 OSCC typically occurs in males, during their sixth to seventh decades of life, with a long history of tobacco and alcohol use. 2 Among young individuals, the occurrence of OSCC is rare, but an increase in the incidence of the malignancy in this population has been observed in different cohorts, accounting for 3.1% to 18.8% of all cases. [3] [4] [5] The variability observed in the incidence of OSCC in young patients is partly explained by the arbitrary use of different cut-off values to determine age groups, making difficult comparison of results obtained by different authors. Although most studies use ages ranging from 30 to 50 years, the majority considers young patients as those aged below 40. [6] [7] [8] In this group of patients, the oral tongue is the most affected site (41.1%-61.3%) and there still is a male predilection, with a male:female ratio of 1.6:1 to 2.6:1. 5, 9, 10 However, a higher proportion of never smokers and never drinkers young women have been described in some studies.
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There is no consensus regarding the prognosis and outcome of OSCC in younger patients. Some studies suggested that OSCC in this group would behave more aggressively, with a poor prognosis, 12 while others demonstrated that young patients have a better prognosis, with higher overall and disease-free survival rates when compared to older patients. 13 However, most of the more recent studies have failed to find any significant difference in the clinical course and prognosis of young patients, suggesting that OSCC behaves in a similar way in both age scenarios. 5, 6, 14 The pathogenesis of OSCC in young patients also represents a highly debatable issue. As young individuals are believed to be exposed for a shorter period to tobacco and alcohol effects, it has been speculated that the etiology of OSCC would differ between younger and older patients. Furthermore, it is also hypothesized that other unknown risk factors could be associated with OSCC development in a younger population. However, few studies have compared the molecular mechanisms of OSCC in both age groups, and most of the investigations are based on immunohistochemistry with small sample sizes, precluding that any strong conclusion is achieved.
Therefore, the aim of this review was to evaluate if the currently available data in the literature support the hypothesis that the molecular basis of OSCC in young patients is significantly different from that observed in older ones.
| GENETIC ALTERATIONS
A large number of studies on genetic alterations of OSCC have attempted to identify molecular markers useful for early detection, prediction of prognosis, and development of targeted therapies. However, despite the advances in the understanding of the molecular mechanisms underlying OSCC development and progression, studies focusing on young population are still limited (Table 1 ). Some authors suggest that OSCC in young individuals has distinct molecular events compared to older individuals, 5, 15 whereas others found a similar molecular profile in the OSCC of both young and older patients. 16, 17 The TP53 tumor suppressor gene is the most frequently altered gene in human cancers. 18 An integrative genomic characterization identified TP53 mutation as a common event and important driver pathway in OSCC. 18 Specifically in the young population, data on the role played by TP53 mutation in the development of OSCC 21 did not observe TP53 mutation in any of their TSCC affecting patients below 40 years of age. As observed, the results obtained were highly discordant and the studies significantly differed regarding their patient population, the exons investigated and detection methods used. In addition, all authors used a small number of cases.
The immunoexpression of p53 has been used as a marker for TP53 mutation in OSCC. 3, 21, 22 Interestingly, a high frequency of p53 positivity was observed in TSCC of young patients even in the absence of TP53 mutations. 21 In two recent studies, p53 expression was more frequent in OSCC of older patients than in younger patients. 3, 22 However, an opposite result was reported by Adduri Tobacco and alcohol use can increase the frequency of TP53 mutation in head and neck squamous cell carcinoma (HNSCC), including oral cancer. 27 However, Lingen et al 21 found a high proportion of p53 overexpression in OSCC of young patients with no previous exposure to tobacco. In a study by Braakhuis et al, 9 the G:C to T:A transversion, known to be associated with tobacco exposure, was not found in the young group with OSCC. Sorensen et al 20 observed that mutations of TP53 occurred only in young patients considered as smokers and/or drinkers. Additionally, two independent cohorts of TSCC did not reveal mutational signature related to smoking in both young and older patients. 16, 17 Although these results demonstrate the importance of tobacco use for the differences in the molecular basis of young patients, the difficulty in determining the actual smoker/drinker/ex-smoker/ex-drinker status of the patients is an important obstacle that must be considered when interpreting the results.
Comparative immunohistochemical analyses of different molecular markers involved in various pathways are also available. OSCC from young patients presents higher expression of EGFR, MMP-9, VEGF-C, and podoplanin when compared to OSCC of older patients. 6, 28, 29 In contrast, higher expression of PCNA and CYP1B1
was observed in older patients. 24, 30 These proteins are related to cell cycle, local invasion, lymphatic growth, cell proliferation, and activation of carcinogenic products. In several other studies, no significant difference was observed between TSCC in young and older patients regarding molecular markers of cell cycle (p53, p21, pRb, MDM2), cell proliferation (Ki67), angiogenic index (vWF), and lymphatic vessel density (podoplanin), as well as the presence of stromal myofibroblasts. 25 Chromosomal alterations were found in almost all cancer types, including OSCC. 5, 15, 37 In a multi-center investigation, the prevalence of DNA ploidy abnormalities and the severity of aneuploidy were higher in patients aged less than 40 years with TSCC than in older patients, 5 suggesting that the frequency and severity of ploidy abnormalities would support the hypothesis of molecular differences in different age groups. Similarly, another study showed that the genomic profile of the younger patients with OSCC, especially the non-smokers, differs from that of older patients in terms of copy gain and loss. The younger non-smokers showed the lowest number of aberrations, while the older smokers showed the highest number of aberrations. 15 The chromosomal alterations of OSCC in patients younger than 40 years were also investigated by Jin et al 37 A recent study revealed that family history of early-onset cancer was associated with a higher risk for head and neck cancer (HNC), including oral cancer, only in young compared with older patients.
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However, further studies are needed to elucidate the biological mechanisms that may explain this association.
| EPIGEN ETIC ALTERATION S
Epigenetic alterations refer to reversible changes in gene expression without alterations in the DNA sequence. The key processes responsible for epigenetic regulation are DNA methylation, histone modifications, and post-transcriptional gene regulation by non-coding RNA. 39 Epigenetic alterations can be involved in the carcinogenesis of OSCC in young patients, but studies in this field are scarce. The most extensively studied epigenetic alteration in human tumors is DNA methylation. 39 Su et al 8 up-regulation of let-7 family miRNAs, let-7f-5p, miR-30b-5p, and let7e-5p in TSCC of young patients (≤30 years) compared to normal tissue. Additionally, up-regulation of let-7c, miR-130a-3p, miR-361-5p, miR-99a-5p, miR-29c-3p was found, and let-7d-5p was associated with more aggressive tumors. However, in this study, 83.3% of patients already had advanced disease and in the aggressive group only patients with recurrences and who died due to the disease were included-this may have influenced the association of miRNAs and the clinical behavior of the tumor.
The cut-off age used in the above studies was different from the age commonly used in the literature and they had small sample sizes.
However, these initial results indicate that there may be some differences in the epigenetic mechanisms of OSCC between the two age groups.
A recent study using genomic and epigenomic data sets from HNSCC identified a cluster that was labeled H3K36. 40 there is currently no available data for a younger population, representing a large opportunity for future OSCC research.
| HUMAN PAPILLOMAVIRUS
Human papillomavirus (HPV) is a small, circular, double-stranded DNA virus that can be either integrated into the host cell nucleus or present in its episomal form. 3, 42 The HPV oncoproteins E6 and E7 stimulate cell proliferation by inactivating p53 and retinoblastoma protein (pRb), respectively. 42 The functional inactivation of pRb results in the release of the E2F that induces an overexpression of p16 protein, leading to cell cycle dysregulation, genetic instability, and proliferative phenotype. 3, 42 Human papillomavirus was recognized as an etiologic agent for oropharyngeal SCC (OPSCC) and HPV-related OPSCC presents different epidemiology, clinical manifestation, histopathological characteristics, and prognosis compared to HPV-negative cancers. 43 The possible involvement of HPV in the etiology of OSCC is more controversial with some authors speculating that the increase of OSCC in young patients could be associated with HPV virus.
Current data regarding the frequency of HPV-positive OSCC in young patients are contradictory with results ranging from 0% to over 58.3%. 3, 9, 14, 42, [44] [45] [46] [47] [48] However, most published studies describe a low frequency of HPV-positive OSCC in younger patients (less than 10%). Interestingly, Kaminagakura et al 14 and Singh et al 42 found a much higher positivity (31.9% and 58.3%) in Brazilian and Indian populations, respectively. This variation in frequency of associated cases in younger patients could be a result of different tumor sites being investigated, the geographic heterogeneity, and the varying HPV detection methods used (Table S1 ).
Immunohistochemical p16 staining is considered as a surrogate marker for HPV-related HNSCC, 45 but there is no consensus on defining p16 positivity. Some authors classified a tumor as p16-positive in case of strong and diffuse nuclear and cytoplasmatic staining in >10% of tumor cells, while others recommend more than 70% of positive tumor cells. 49 Regarding the analysis of p16 in young patients, positivity criteria have also been variable, ranging from 40% to 75% of tumor cells. 3, 42, 45 Consequently, p16 expression was reported in 15% to 44% of young patients with OSCC. 3, 47 In studies that compared p16 expression between young and older patients, there were no statistically significant differences found. 3, 6, 14 As the presence of HPV leads to p53 inactivation and p16 overexpression, some studies have analyzed the utility of the simultaneous expression of both proteins as an indicator of HPV infection.
Rushatamukayanunt et al 3 observed that p16 overexpression with decreased levels of p53 staining was more frequent in young patients (12.5%) than older patients (5%). However, neither the isolated nor the combined expression of p16 and p53 correlated with the presence of HPV. van Monsjou et al 45 verified that the combination of both p16 overexpression and low levels of p53 did not result in a higher sensitivity for prediction of the HPV presence in HNSCC of young patients.
It is important to highlight that the identification of HPV does not always reflect the presence of its biologically active form, and the virus may be present without necessarily being involved in the etiology of the tumor. 50 
| CONCLUSION
Although recent efforts have been made to better understand the molecular differences between young and older patients with OSCC, the significant methodological limitations found in most published studies, including small sample sizes, tumors from different anatomical subsites, the age at which patients are classified as young or old, the lack of control groups and several laboratorial variabilities, preclude any strong conclusions.
However, evidence from well-designed studies has demonstrated few differences in the genetic profile of these two groups. Epigenetic status of OSCC in young patients has barely been evaluated to date, and it needs to be fully investigated. The importance of HPV infection in this group of patients seems to be small and may not significantly contribute to its pathogenesis.
Finally, although the molecular basis of OSCC is likely to differ between young and older patients given its epidemiological features and the lower influence of common risk factors, better-designed studies are required to confirm any real differences.
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